| 1 |
Jackson AM, Pinelli DF. Understanding the impact of HLA molecular mismatch in solid organ transplantation: Are we there yet？[J]. Am J Transplant, 2021, 21(1): 9-10.
|
| 2 |
Nakamura T, Shirouzu T, Nakata K, et al. The role of major histocompatibility complex in organ transplantation-donor specific anti-major histocompatibility complex antibodies analysis goes to the next stage[J]. Int J Mol Sci, 2019, 20(18): 4544.
|
| 3 |
石强．HLA分型方法的发展及其在器官移植中的作用[J/CD]. 实用器官移植电子杂志，2018, 6(4): 251-253.
|
| 4 |
Tambur AR, Campbell P, Chong AS, et al. Sensitization in transplantation: assessment of risk (STAR) 2019 Working Group Meeting Report[J]. Am J Transplant, 2020, 20(10): 2652-2668.
|
| 5 |
Vo AA, Aubert O, Haas M, et al. Clinical relevance of posttransplant DSAs in patients receiving desensitization for HLA-incompatible kidney transplantation[J]. Transplantation, 2019, 103(12): 2666-2674.
|
| 6 |
Su JA, Baxter-Lowe LA, Kantor PF, et al. The clinical impact of donor-specific antibodies on antibody-mediated rejection and long-term prognosis after heart transplantation[J]. Curr Opin Organ Transplant, 2019, 24(3): 245-251.
|
| 7 |
Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection[J]. Am J Transplant, 2020, 20(9): 2318-2331.
|
| 8 |
Maurice JB, Nwaogu A, Gouda M, et al. Acute antibody-mediated rejection in liver transplantation: impact and applicability of the Banff working group on liver allograft pathology 2016 criteria[J]. Hum Pathol, 2022, 127: 67-77.
|
| 9 |
Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation[J]. J Heart Lung Transplant, 2016, 35(4): 397-406.
|
| 10 |
Lefaucheur C, Louis K, Philippe A, et al. The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond[J]. Kidney Int, 2021, 100(4): 787-798.
|
| 11 |
Senev A, Coemans M, Lerut E, et al. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome[J]. Am J Transplant, 2019, 19(3): 763-780.
|
| 12 |
Grafft CA, Cornell LD, Gloor JM, et al. Antibody-mediated rejection following transplantation from an HLA-identical sibling[J]. Nephrol Dial Transplant, 2010, 25(1): 307-310.
|
| 13 |
Opelz G, Collaorative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies[J]. Lancet, 2005, 365(9470): 1570-1576.
|
| 14 |
Thomson AW. A well-armed approach drives relevant non-HLA antibody targets into the open[J]. Transplantation, 2022, 106(7): 1310-1311.
|
| 15 |
Butler CL, Hickey MJ, Jiang N, et al. Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: from bench to bedside[J]. Am J Transplant, 2020, 20(10): 2768-2780.
|
| 16 |
Lammerts RGM, Altulea D, Hepkema BG, et al. Antigen and cell-based assays for the detection of non-HLA antibodies[J]. Front Immunol, 2022, 13: 864671.
|
| 17 |
Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection[J]. Kidney Int, 2011, 79(6): 655-662.
|
| 18 |
李树欣，武康，袁清，等. 肾移植术后新生抗内皮细胞抗体与术后不良事件的相关性[J]. 中华器官移植杂志，2017, 38(5): 282-286.
|
| 19 |
Delville M, Lamarthée B, Pagie S, et al. Early acute microvascular kidney transplant rejection in the absence of anti-HLA antibodies is associated with preformed IgG antibodies against diverse glomerular endothelial cell antigens[J]. J Am Soc Nephrol, 2019, 30(4): 692-709.
|
| 20 |
Vermehren D, Sumitran-Holgersson S. Isolation of precursor endothelial cells from peripheral blood for donor-specific crossmatching before organ transplantation[J]. Transplantation, 2002, 74(11): 1479-1486.
|
| 21 |
Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation[J]. Transplantation, 2009, 87(4): 549-556.
|
| 22 |
Yu S, Huh HJ, Lee KW, et al. Pre-Transplant angiotensin Ⅱ type 1 receptor antibodies and anti-endothelial cell antibodies predict graft function and allograft rejection in a low-risk kidney transplantation setting[J]. Ann Lab Med, 2020, 40(5): 398-408.
|
| 23 |
Lamarthée B, Burger C, Leclaire C, et al. CRISPR/Cas9-engineered HLA-deleted glomerular endothelial cells as a tool to predict pathogenic non-HLA antibodies in kidney transplant recipients[J]. J Am Soc Nephrol, 2021, 32(12): 3231-3251.
|
| 24 |
Sutherland SM, Li L, Sigdel TK, et al. Protein microarrays identify antibodies to protein kinase Cζ that are associated with a greater risk of allograft loss in pediatric renal transplant recipients[J]. Kidney Int, 2009, 76(12): 1277-1283.
|
| 25 |
Clotet-Freixas S, Kotlyar M, McEvoy CM, et al. Increased autoantibodies against Ro/SS-A, CENP-B, and La/SS-B in patients with kidney allograft antibody-mediated rejection[J]. Transplant Direct, 2021, 7(10): e768.
|
| 26 |
Reinsmoen NL. Compelling scientific and clinical evidence that non-HLA specific antibodies impact graft outcome independently and in concert with donor HLA specific antibodies[J]. Hum Immunol, 2019, 80(8): 555-560.
|
| 27 |
Lefaucheur C, Viglietti D, Bouatou Y, et al. Non-HLA agonistic anti-angiotensin Ⅱ type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients[J]. Kidney Int, 2019, 96(1): 189-201.
|
| 28 |
Liu C, Kang ZY, Yin Z, et al. Levels of angiotensin Ⅱ type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients[J]. Transpl Immunol, 2022, 74: 101674.
|
| 29 |
Aguilera I, Sousa JM, Gavilán F, et al. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation[J]. Liver Transpl, 2004, 10(9): 1166-1172.
|
| 30 |
Aguilera I, Sousa JM, Praena JM, et al. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation[J]. Clin Transplant, 2011, 25(2): 207-212.
|
| 31 |
Akgul SU, Oguz FS, Çalişkan Y, et al. The effect of glutathion S-transferase polymoprhisms and anti-GSTT1 antibodies on allograft functions in recipients of renal transplant[J]. Transplant Proc, 2012, 44(6): 1679-1684.
|
| 32 |
Kamburova EG, Gruijters ML, Kardol-Hoefnagel T, et al. Antibodies against ARHGDIB are associated with long-term kidney graft loss[J]. Am J Transplant, 2019, 19(12): 3335-3344.
|
| 33 |
Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney-transplant rejection[J]. N Engl J Med, 2007, 357(13): 1293-1300.
|
| 34 |
Baranwal AK, Bhat DK, Goswami S, et al. Clinical relevance of major histocompatibility complex class Ⅰ chain-related molecule A (MICA) antibodies in live donor renal transplantation - Indian Experience[J]. Scand J Immunol, 2020, 92(5): e12923.
|
| 35 |
Baranwal AK, Mehra NK. Major histocompatibility complex class Ⅰ chain-related A (MICA) molecules: relevance in solid organ transplantation[J]. Front Immunol, 2017, 8: 182.
|
| 36 |
Kamburova EG, Gruijters ML, Kardol-Hoefnagel T, et al. Antibodies against ARHGDIB are associated with long-term kidney graft loss[J]. Am J Transplant, 2019, 19(12): 3335-3344.
|
| 37 |
Comoli P, Cioni M, Ray B, et al. Anti-glutathione S-transferase theta 1 antibodies correlate with graft loss in non-sensitized pediatric kidney recipients[J]. Front Med (Lausanne), 2022, 9: 1035400.
|
| 38 |
庄少勇，陈若洋，李大伟，等. 肾移植术后非HLA抗体与体液性排斥反应相关性研究[J]. 中华器官移植杂志，2022, 43(6): 328-333.
|
| 39 |
Senev A, Ray B, Lerut E, et al. The pre-transplant non-HLA antibody burden associates with the development of histology of antibody-mediated rejection after kidney transplantation[J]. Front Immunol, 2022, 13: 809059.
|
| 40 |
Jackson AM, Delville M, Lamarthée B, et al. Sensitization to endothelial cell antigens: unraveling the cause or effect paradox[J]. Hum Immunol, 2019, 80(8): 614-620.
|